blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2262367

EP2262367 - ORAL PHARMACEUTICAL COMPOSITIONS OF BUPRENORPHINE AND METHOD OF USE [Right-click to bookmark this link]
StatusThe application has been refused
Status updated on  14.10.2022
Database last updated on 24.04.2024
Most recent event   Tooltip14.10.2022Refusal of applicationpublished on 16.11.2022  [2022/46]
Applicant(s)For all designated states
Relmada Therapeutics, Inc.
146 Medinah Drive
Blue Bell, PA 19422-3212 / US
[2012/16]
Former [2010/51]For all designated states
Theraquest Biosciences, Inc.
146 Medinah Drive
Blue Bell, PA 19422-3212 / US
Inventor(s)01 / BABUL, Najib
146 Medinah Drive
Blue Bell PA 19422-3212 / US
02 / REHNI, Ashish, Kumar
39 Gurmat Colony Sular Road
Patiala 147001 / IN
 [2010/51]
Representative(s)Forresters IP LLP
Skygarden
Erika-Mann-Straße 11
80636 München / DE
[N/P]
Former [2013/37]Bond, Christopher William, et al
Forresters
Skygarden
Erika-Mann-Strasse 11
80636 München / DE
Former [2012/13]Walker, Ross Thomson, et al
Forrester & Boehmert
SkyGarden
Erika-Mann-Strasse 11
80636 München / DE
Former [2010/51]Walker, Ross Thomson, et al
Forrester & Boehmert Pettenkoferstrasse 20-22
80336 München / DE
Application number, filing date09719755.209.03.2009
[2010/51]
WO2009US01502
Priority number, dateUS20080064505P08.03.2008         Original published format: US 64505 P
[2010/51]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2009114118
Date:17.09.2009
Language:EN
[2009/38]
Type: A2 Application without search report 
No.:EP2262367
Date:22.12.2010
Language:EN
The application published by WIPO in one of the EPO official languages on 17.09.2009 takes the place of the publication of the European patent application.
[2010/51]
Search report(s)International search report - published on:US18.03.2010
(Supplementary) European search report - dispatched on:EP21.03.2011
ClassificationIPC:A01N43/42, A61K31/44
[2010/51]
CPC:
C07D489/12 (EP,US); A61K31/485 (EP,US); A61K9/1635 (EP,US);
A61K9/1652 (EP,US); A61K9/1664 (EP,US); A61K9/2018 (EP,US);
A61K9/2027 (EP,US); A61K9/2054 (EP,US); A61K9/2866 (EP,US);
A61K9/5078 (EP,US); A61P13/00 (EP); A61P25/30 (EP);
A61P25/36 (EP); A61P31/22 (EP); A61K9/0004 (EP,US) (-)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2010/51]
TitleGerman:PHARMAZEUTISCHE ORALZUSAMMENSETZUNGEN VON BUPRENORPHIN UND VERFAHREN FÜR IHRE VERWENDUNG[2010/51]
English:ORAL PHARMACEUTICAL COMPOSITIONS OF BUPRENORPHINE AND METHOD OF USE[2010/51]
French:COMPOSITIONS PHARMACEUTIQUES ORALES DE BUPRÉNORPHINE ET PROCÉDÉ D UTILISATION[2010/51]
Entry into regional phase08.10.2010National basic fee paid 
08.10.2010Search fee paid 
08.10.2010Designation fee(s) paid 
08.10.2010Examination fee paid 
Examination procedure08.10.2010Examination requested  [2010/51]
17.10.2011Amendment by applicant (claims and/or description)
28.03.2013Despatch of a communication from the examining division (Time limit: M06)
08.01.2014Reply to a communication from the examining division
15.05.2015Despatch of a communication from the examining division (Time limit: M06)
22.12.2015Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time
09.02.2016Reply to a communication from the examining division
08.03.2018Date of oral proceedings
29.03.2018Despatch of communication that the application is refused, reason: substantive examination [2022/46]
29.03.2018Minutes of oral proceedings despatched
28.09.2022Application refused, date of legal effect [2022/46]
Appeal following examination29.05.2018Appeal received No.  T2418/18
25.07.2018Statement of grounds filed
28.09.2022Result of appeal procedure: appeal of the applicant withdrawn
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  28.03.2013
Request for further processing for:The application is deemed to be withdrawn due to failure to reply to the examination report
09.02.2016Request for further processing filed
09.02.2016Full payment received (date of receipt of payment)
Request granted
19.02.2016Decision despatched
The application is deemed to be withdrawn due to failure to reply to the examination report
08.01.2014Request for further processing filed
08.01.2014Full payment received (date of receipt of payment)
Request granted
29.01.2014Decision despatched
Fees paidRenewal fee
23.08.2011Renewal fee patent year 03
14.03.2012Renewal fee patent year 04
11.03.2013Renewal fee patent year 05
12.03.2014Renewal fee patent year 06
10.03.2015Renewal fee patent year 07
10.03.2016Renewal fee patent year 08
10.03.2017Renewal fee patent year 09
13.03.2018Renewal fee patent year 10
13.03.2019Renewal fee patent year 11
10.03.2020Renewal fee patent year 12
09.03.2021Renewal fee patent year 13
16.03.2022Renewal fee patent year 14
Penalty fee
Additional fee for renewal fee
31.03.201103   M06   Fee paid on   23.08.2011
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[X]US2003124185  (OSHLACK BENJAMIN [US], et al) [X] 1-15 * paragraphs [0079] , [0 88] - [0093] - [ 101] , [ 107] - [0182] * * Examples ** Claims *;
 [X]WO2007087452  (THERAQUEST BIOSCIENCES LLC [US], et al) [X] 1-10,12-15 * paragraphs [0071] , [0 88] - [0156] - [ 274] , [ 290] , [ 342] , [ 344] , [ 349] , [ 361] , [ 387] - [0410] * * in particular * * paragraphs [0148] - [0156] * * Examples * * Claims *;
 [X]EP1849460  (ALZA CORP [US]) [X] 1-15 * paragraph [0082] - paragraph [0187] * * Examples * * Claims, in particular * * claims 11, 68 *;
 [X]WO2008027442  (THERAQUEST BIOSCIENCES LLC [US], et al) [X] 1-10,12-15 * paragraphs [0052] , [ 211] , [ 335] , [ 383] - [0421] * * in particular * * paragraph [0419] * * Examples * * Claims *
International search[X]US2008026052  (SCHOENHARD GRANT L [US]);
 [Y]US7270830  (REIDENBERG BRUCE E [US], et al);
 [A]US2003198675  (REDER ROBERT F [US], et al);
 [A]US2005075361  (WANG JHI-JOUNG [TW])
ExaminationCA2126611
 EP0631781
 US2002010127
 WO02100382
 WO2007013975
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.